Tag
This study demonstrates that nearly half of islet secretory function is preserved following total pancreatectomy with islet autotransplantation (TPIAT), independent of preoperative glycaemic status or prior pancreatic surgery. Continuous gl
This study evaluates gender-based differences in hypoglycaemia symptoms and frequency among people with type 1 and insulin-treated type 2 diabetes using continuous glucose monitoring in real-world settings.
A large real-world study found that public implementation of intermittently scanned continuous glucose monitoring in insulin-treated type 2 diabetes was linked to better HbA1c, fewer acute diabetes hospitalizations, shorter stays, and lower
A six-week native GIP infusion did not improve glucose control in type 2 diabetes, either alone or added to semaglutide, despite raising circulating GIP levels.
The FreeDM2 trial demonstrates that real-time CGM significantly improves HbA1c levels compared to SMBG in adults with type 2 diabetes on basal insulin and modern therapies, with sustained benefits over 32 weeks.
The updated glucose management indicator (uGMI) significantly improves alignment with HbA1c, reducing discordance, particularly in high and low glucose ranges, offering clinicians a more reliable tool for diabetes monitoring.
A randomized trial of 205 pregnant women with gestational diabetes found that adjunctive flash glucose monitoring did not improve time-in-range glucose measurements compared to standard self-monitoring. However, the device was associated wi
This study evaluates HbA1c, glycated albumin, and fructosamine against CGM in dialysis patients. While HbA1c and glycated albumin show strong correlations with mean glucose, significant clinical biases from ESA use, BMI, and dialysis modali
This post hoc analysis of the WISDM study evaluates whether 52 weeks of continuous glucose monitoring (CGM) improves impaired awareness of hypoglycemia (IAH) in older adults. While severe events decreased, physiological awareness remained l
Systematic intensive therapy combined with continuous glucose monitoring significantly improves glycemic control in adults with type 1 diabetes not meeting targets, without increasing adverse events.
Automated insulin delivery (AID) significantly improves glycemic control in insulin-treated type 2 diabetes, demonstrating greater HbA1c reduction and increased time in target glucose range compared to traditional insulin delivery methods.
The ADA’s 2024 Standards refocus diabetes care around cardiorenal protection, expanded use of GLP‑1 and SGLT2 therapies, wider adoption of glucose‑sensing technology, and integrated obesity management.
A 2-week randomized, double-blind, placebo-controlled crossover trial demonstrated that Kanzaki mulberry leaf and water chestnut tea significantly reduces postprandial glucose variability without adverse safety signals, supporting its poten
The DipGluMo trial found that real-time continuous glucose monitoring does not improve perinatal outcomes versus self-monitoring in gestational diabetes, but is preferred by patients for ease of use.
Discover the key precautions and expert advice for women with diabetes considering pregnancy, blending the latest science with real-life advice.
